Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bond

Showing results (771-780 of 784) with videos related to

Pageof 79
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2018
Evaluation of a PET Radioligand to Image Soumen Paul, Mohammad B Haskali, Jeih-San Liow, et al.
Leukemia|July 17, 2025
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewalDanielle R Bond, Sean M Burnard, Kumar Uddipto, et al.
Science (New York, N.Y.)|October 9, 2004
Polarization observations with the Cosmic Background ImagerA C S Readhead, S T Myers, T J Pearson, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-oneRobert O Hughes, John K Walker, D Joseph Rogier, et al.
Monthly Notices of the Royal Astronomical Society|August 6, 2020
On the redshift distribution and physical properties of ACT-selected DSFGsT Su, T A Marriage, V Asboth, et al.
Journal of Medicinal Chemistry|August 24, 2010
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular diseaseDaniel P Becker, Thomas E Barta, Louis J Bedell, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitorsDafydd R Owen, John K Walker, E Jon Jacobsen, et al.
Physical Review Letters|May 1, 2001
Cosmology from MAXIMA-1, BOOMERANG, and COBE DMR cosmic microwave background observationsA H Jaffe, P A Ade, A Balbi, et al.
Pageof 79

Showing results (771-780 of 784) with videos related to

Sort By:
Pageof 79
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2018
Evaluation of a PET Radioligand to Image Soumen Paul, Mohammad B Haskali, Jeih-San Liow, et al.
Leukemia|July 17, 2025
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewalDanielle R Bond, Sean M Burnard, Kumar Uddipto, et al.
Science (New York, N.Y.)|October 9, 2004
Polarization observations with the Cosmic Background ImagerA C S Readhead, S T Myers, T J Pearson, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-oneRobert O Hughes, John K Walker, D Joseph Rogier, et al.
Monthly Notices of the Royal Astronomical Society|August 6, 2020
On the redshift distribution and physical properties of ACT-selected DSFGsT Su, T A Marriage, V Asboth, et al.
Journal of Medicinal Chemistry|August 24, 2010
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular diseaseDaniel P Becker, Thomas E Barta, Louis J Bedell, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitorsDafydd R Owen, John K Walker, E Jon Jacobsen, et al.
Physical Review Letters|May 1, 2001
Cosmology from MAXIMA-1, BOOMERANG, and COBE DMR cosmic microwave background observationsA H Jaffe, P A Ade, A Balbi, et al.
Pageof 79